After four previous attempts, Takeda Pharmaceutical Co. plans to buy rival Shire PLC (SHPG) in a $62 billion overseas deal th♍at market the largest ever by a Japanese firm, Tuesday.

The acquisition of U.K.-based Shire would give Takeda a broader market as well as more drugs like Shire’s Adderall, an attention-def🙈icit hyperactivity treatment. Other drugs could provide windfalls with their treatment of rare diseases like hemophilia, which have higher profit margins. “The two combined create a rich pipeline in all stages—early and late stage, which is very important," Weber told . “We are in a good momentum and in a strong position.”

Just last month, Allergan PLC declined to bid for Shire after the U.K. company rejected Takeda’s bid for $60 billion. Shire relented on Takeda's fifth proposal. Takeda plans to secure a bridge loan facility from financial firms like JPMorgan Chase, MUFG Bank and others for about $31 billion. Weber said that loan will be refinanced with long-term, hybrid debt and cash. (See also: 澳洲幸运5开奖号码历史查询:Allergan Declines to Bid on Shire.)

Hot Mergers Market in Health Care

The cash-and-stock deal will put Takeda among the top 10 top companies in the global pharmaceutic🤡al industry.

The 澳洲幸运5开奖号码历史查询:mergers and acquisitions market has been especially active this year with more mega-deals, those valued over $5 billion like Takeda’s planned takeover, jumping 67% in the first quarter of 2018 compared to the same quarter the year prior, according to a recent Morgan Stanley analysis. (See also: 澳洲幸运5开奖号码历史查询:What's Be𝔍hind Cigna's $67B Express Scripts Buy?)

Including debt, Takeda’s takeover is worth more than $80 billion. Shares of Shire have rallied 29.5% in the past three months amid acquisition interest. The stock was up 1.3% early in Tues꧟day’s session.